
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is a compelling investment opportunity with a differentiated profile in the competitive HAE market, strong clinical data supporting their bradykinin B2 receptor antagonists, and significant market potential of ~€1B in peak sales. Their lead candidate, deucrictibant, has shown superiority in efficacy and tolerability in both on-demand and prophylactic settings compared to injectable options, with potential for even greater market share through physician willingness to switch patients from existing treatments. Recent financial updates also show strong cash position, providing runway into 2028.
Bears say
Pharvaris is a late-stage biopharmaceutical company with a negative outlook due to potential risks such as an increasingly crowded market for HAE treatments, experimental XR formulation being different from initial studies, and potential safety concerns. However, the company currently has a strong financial standing with €318 million on its balance sheet and a $40/share valuation based on a 10-year discounted cash flow analysis, assuming successful approval and launch of deucrictibant IR. The lack of diversity or social initiatives among senior management may also be a concern for some investors.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares